Home / Articles / Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors

Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors

Ol'ga Nikolaevna Zefirova 1
Ol'ga Nikolaevna Zefirova
, 
Nikolai Serafimovich Zefirov 1
Nikolai Serafimovich Zefirov
1 M. V. Lomonosov Moscow State University, Department of Chemistry
10.1070/RC2001v070n04ABEH000654
Published 30 November 2000
Communication , Volume 70, Issue 4, 333-355
6
Share
Cite this
GOST
 | 
Cite this
GOST
Copy cite
Zefirova O. N., Zefirov N. S. Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors // Russian Chemical Reviews. 2001. Vol. 70. No. 4. pp. 333-355.
GOST all authors (up to 50)
Copy cite
Zefirova O. N., Zefirov N. S. Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors // Russian Chemical Reviews. 2001. Vol. 70. No. 4. pp. 333-355.
RIS
 | 
Cite this
RIS
Copy cite
TY - JOUR
DO - 10.1070/RC2001v070n04ABEH000654
UR - https://rcr.colab.ws/publications/10.1070/RC2001v070n04ABEH000654
TI - Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors
T2 - Russian Chemical Reviews
AU - Zefirova, Ol'ga Nikolaevna
AU - Zefirov, Nikolai Serafimovich
PY - 2001
DA - 2000/11/30
PB - ANO Editorial Board of the journal Uspekhi Khimii
SP - 333-355
IS - 4
VL - 70
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors)
Copy cite
@article{2001_Zefirova,
author = {Ol'ga Nikolaevna Zefirova and Nikolai Serafimovich Zefirov},
title = {Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors},
journal = {Russian Chemical Reviews},
year = {2001},
volume = {70},
publisher = {ANO Editorial Board of the journal Uspekhi Khimii},
month = {Nov},
url = {https://rcr.colab.ws/publications/10.1070/RC2001v070n04ABEH000654},
number = {4},
pages = {333--355},
doi = {10.1070/RC2001v070n04ABEH000654}
}
MLA
Cite this
MLA
Copy cite
Zefirova, Ol'ga Nikolaevna, and Nikolai Serafimovich Zefirov. “Physiologically active compounds interacting with serotonin (5-hydroxytryptamine) receptors.” Russian Chemical Reviews, vol. 70, no. 4, Nov. 2001, pp. 333-355. https://rcr.colab.ws/publications/10.1070/RC2001v070n04ABEH000654.
Views / Visits / Downloads
16 / 16 / 3

Abstract

The data on the structures of organic compounds active with respect to serotonin (5-hydroxytryptamine) receptors are systematised. Various aspects of their design are considered. The bibliography includes 296 references.

References

1.
1
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1948
2.
2
A. A. Krasnovskii
Zhur. Fiz. Khim. , 1956
3.
3
M. F. Shostakovskii
"Prostye Vinilovye Efiry" (Vinyl Ethers) , 1952
7.
Current advances and trends in the treatment of depression.
Blier P., de Montigny C.
Trends in Pharmacological Sciences , 1994
8.
Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents.
Fletcher A., Cliffe I.A., Dourish C.T.
Trends in Pharmacological Sciences , 1993
9.
Neuropharmacology of anxiety: perspectives and prospects.
Hamon M.
Trends in Pharmacological Sciences , 1994
11.
11
T. T. Bannister
Diss. Abstr. , 1959
14.
14
V. B. Evstigneev
Zhur. Fiz. Khim. , 1958
16.
(+)-cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist
Arvidsson L.E., Johansson A.M., Hacksell U., Nilsson J.L., Svewnsson K., Hjorth S., Magnusson T., Carlsson A., Andersson B., Wikstroem H.
Journal of Medicinal Chemistry , 1987
17.
A 3 dimensional model for 5-HT1A-receptor agonists based on stereoselective methyl-substituted and conformationally restricted analogs of 8-hydroxy-2-(dipropylamino)tetralin
Mellin C., Vallgaarda J., Nelson D.L., Bjoerk L., Yu H., Anden N.E., Csoeregh I., Arvidsson L.E., Hacksell U.
Journal of Medicinal Chemistry , 1991
18.
18
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1951
19.
Resolved cis-10-hydroxy-4-n-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinoline: central serotonin stimulating properties
Wikstroem H., Andersson B., Elebring T., Jacyno J., Allinger N.L., Svensson K., Carlsson A., Sundell S.
Journal of Medicinal Chemistry , 1987
20.
Derivatives of (R)- and (S)-5-Fluoro-8-hydroxy-2-(dipropylamino)tetralin:  Synthesis and Interactions with 5-HT1A Receptors
Backlund Höök B., Cortizo L., Johansson A.M., Westlind-Danielsson A., Mohell N., Hacksell U.
Journal of Medicinal Chemistry , 1996
21.
21
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1958
22.
(S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: a putative 5-HT1A-receptor antagonist
Hillver S.E., Bjoerk L., Li Y.L., Svensson B., Ross S., Anden N.E., Hacksell U.
Journal of Medicinal Chemistry , 1990
23.
trans-2-Aryl-N,N-dipropylcyclopropylamines:  Synthesis and Interactions with 5-HT1A Receptors
Vallgårda J., Appelberg U., Arvidsson L., Hjorth S., Svensson B.E., Hacksell U.
Journal of Medicinal Chemistry , 1996
24.
11-Substituted (R)-Aporphines:  Synthesis, Pharmacology, and Modeling of D2A and 5-HT1A Receptor Interactions
Hedberg M.H., Linnanen T., Jansen J.M., Nordvall G., Hjorth S., Unelius L., Johansson A.M.
Journal of Medicinal Chemistry , 1996
25.
10-Substituted 11-Oxygenated (R)-Aporphines:  Synthesis, Pharmacology, and Modeling of 5-HT1A Receptor Interactions
Hedberg M.H., Jansen J.M., Nordvall G., Hjorth S., Unelius L., Johansson A.M.
Journal of Medicinal Chemistry , 1996
26.
5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae
Baxter G.S., Craig D.A., Clarke D.E.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1991
27.
Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline
Titus R.D., Kornfeld E.C., Jones N.D., Clemens J.A., Smalstig E.B., Fuller R.W., Hahn R.A., Hynes M.D., Mason N.R.
Journal of Medicinal Chemistry , 1983
28.
Synthesis and Biological Activities of (R)-5,6-Dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and Its Metabolites
Heier R.F., Dolak L.A., Duncan J.N., Hyslop D.K., Lipton M.F., Martin I.J., Mauragis M.A., Piercey M.F., Nichols N.F., Schreur P.J., Smith M.W., Moon M.W.
Journal of Medicinal Chemistry , 1997
29.
The selective labelling of central 5-HT1A receptor binding sites by [3H]5-methoxy-3-(di-n-propylamino)chroman.
Cossery J.M., Gozlan H., Spampinato U., Perdicakis C., Guillaumet G., Pichat L., Hamon M.
European Journal of Pharmacology , 1987
30.
Synthesis of Novel 5-Substituted 3-Amino-3,4-dihydro-2H-1-benzopyran Derivatives and Their Interactions with the 5-HT1A Receptor
Hammarberg E., Nordvall G., Leideborg R., Nylöf M., Hanson S., Johansson L., Thorberg S., Tolf B., Jerning E., Torell Svantesson G., Mohell N., Ahlgren C., Westlind-Danielsson A., Csöregh I., Johansson R., et. al.
Journal of Medicinal Chemistry , 2000
31.
Buspirone
Goa K.L., Ward A.
Drugs , 1986
36.
The concept of selectivity in 5-HT receptor research.
Van Wijngaarden I., Tulp M.T., Soudijn W.
European Journal of Pharmacology Molecular Pharmacology , 1990
38.
Analogs of the 5-HT1A serotonin antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine with reduced .alpha.1-adrenergic affinity
Raghupathi R.K., Rydelek-Fitzgerald L., Teitler M., Glennon R.A.
Journal of Medicinal Chemistry , 1991
39.
Structure-affinity relationship studies on 5-HT1A receptor ligands. 1. Heterobicyclic phenylpiperazines with N4-alkyl substituents
van Steen B.J., van Wijngaarden I., Tulp M.T., Soudijn W.
Journal of Medicinal Chemistry , 1993
40.
Structure-Affinity Relationship Studies on 5-HT1A receptor Ligands. 2. Heterobicyclic Phenylpiperazines with N4-Aralkyl Substituents
van Steen B.J., van Wijngaarden I., Tulp M.T., Soudijn W.
Journal of Medicinal Chemistry , 1994
42.
5-(Nonyloxy)tryptamine: A Novel High-Affinity 5-HT1D.beta. Serotonin Receptor Agonist
Glennon R.A., Hong S., Dukat M., Teitler M., Davis K.
Journal of Medicinal Chemistry , 1994
43.
Binding of O-Alkyl Derivatives of Serotonin at Human 5-HT1Dβ Receptors
Glennon R.A., Hong S., Bondarev M., Law H., Dukat M., Rakhit S., Power P., Fan E., Kinneau D., Kamboj R., Teitler M., Herrick-Davis K., Smith C.
Journal of Medicinal Chemistry , 1996
45.
Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378
Sharp T., Backus L.I., Hjorth S., Bramwell S.R., Grahame-Smith D.G.
European Journal of Pharmacology , 1990
47.
Agonist activity of a novel compound, 1-[3-(3,4-methylenedioxyphenoxy) propyl]-4-phenyl piperazine (BP-554), at central 5-HT1A receptors
Matsuda T., Yeon Hee Seong, Aono H., Kanda T., Baba A., Saito K., Tobe A., Iwata H.
European Journal of Pharmacology , 1989
48.
5-HT2 receptor subtypes: A family re-united?
Baxter G., Kennett G., Blackburn T., Blaney F.
Trends in Pharmacological Sciences , 1995
49.
New Benzocycloalkylpiperazines, Potent and Selective 5-HT1A Receptor Ligands
El Ahmad Y., Laurent E., Maillet P., Talab A., Teste J.F., Dokhan R., Tran G., Ollivier R.
Journal of Medicinal Chemistry , 1997
51.
Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines
Peglion J., Canton H., Bervoets K., Audinot V., Brocco M., Gobert A., Le Marouille-Girardon S., Millan M.J.
Journal of Medicinal Chemistry , 1995
52.
Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 1. 2-[[4-(o-Methoxyphenyl)piperazin-1-yl]methyl]-1,3- dioxoperhydroimidazo[1,5-a]pyridine:  A Selective 5-HT1A Receptor Agonist
López-Rodríguez M.L., Rosado M.L., Benhamú B., Morcillo M.J., Sanz A.M., Orensanz L., Beneitez M.E., Fuentes J.A., Manzanares J.
Journal of Medicinal Chemistry , 1996
56.
3,4-Dihydro-3-amino-2H-1-benzopyran Derivatives as 5-HT1A Receptor Ligands and Potential Anxiolytic Agents. 1. Synthesis and Structure-Activity Relationship Studies
Podona T., Guardiola-Lemaitre B., Caignard D., Adam G., Pfeiffer B., Renard P., Guillaumet G.
Journal of Medicinal Chemistry , 1994
57.
Quantitative Analysis of the Structural Requirements for Blockade of the N-Methyl-d-aspartate Receptor at the Phencyclidine Binding Site
Kroemer R.T., Koutsilieri E., Hecht P., Liedl K.R., Riederer P., Kornhuber J.
Journal of Medicinal Chemistry , 1998
58.
58
N. E. Khomutov
1953
59.
59
H. Linshitz
"Research in Photosynthesis" , 1957
60.
3-Amino-3,4-dihydro-2H-1-benzopyran Derivatives as 5-HT1A Receptor Ligands and Potential Anxiolytic Agents. 2. Synthesis and Quantitative Structure−Activity Relationship Studies of Spiro[pyrrolidine- and piperidine-2,3‘(2‘H)-benzopyrans]
Comoy C., Marot C., Podona T., Baudin M., Morin-Allory L., Guillaumet G., Pfeiffer B., Caignard D., Renard P., Rettori M., Adam G., Guardiola-Lemaître B.
Journal of Medicinal Chemistry , 1996
63.
Electrophysiology of the 5-HT1A ligand MDL 73005EF in the rat hippocampal slice
Van den Hooff P., Galvan M.
European Journal of Pharmacology , 1991
64.
New Generation Dopaminergic Agents. 1. Discovery of a Novel Scaffold Which Embraces the D2 Agonist Pharmacophore. Structure−Activity Relationships of a Series of 2-(Aminomethyl)chromans
Mewshaw R.E., Kavanagh J., Stack G., Marquis K.L., Shi X., Kagan M.Z., Webb M.B., Katz A.H., Park A., Kang Y.H., Abou-Gharbia M., Scerni R., Wasik T., Cortes-Burgos L., Spangler T., et. al.
Journal of Medicinal Chemistry , 1997
65.
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 6. Role of the Dioxane Unit on Selectivity for α1-Adrenoreceptor Subtypes
Quaglia W., Pigini M., Piergentili A., Giannella M., Marucci G., Poggesi E., Leonardi A., Melchiorre C.
Journal of Medicinal Chemistry , 1999
66.
5-HT1A- versus D2-Receptor Selectivity of Flesinoxan and Analogous N 4-Substituted N 1-Arylpiperazines
Kuipers W., Kruse C.G., van Wijngaarden I., Standaar P.J., Tulp M.T., Veldman N., Spek A.L., IJzerman A.P.
Journal of Medicinal Chemistry , 1997
67.
Design and Synthesis of a Series of 6-Substituted-2-pyridinylmethylamine Derivatives as Novel, High-Affinity, Selective Agonists at 5-HT1A Receptors
Vacher B., Bonnaud B., Funes P., Jubault N., Koek W., Assié M., Cosi C.
Journal of Medicinal Chemistry , 1998
68.
Novel Derivatives of 2-Pyridinemethylamine as Selective, Potent, and Orally Active Agonists at 5-HT1A Receptors
Vacher B., Bonnaud B., Funes P., Jubault N., Koek W., Assié M., Cosi C., Kleven M.
Journal of Medicinal Chemistry , 1999
70.
3-Benzisothiazolylpiperazine Derivatives as Potential Atypical Antipsychotic Agents
Howard H.R., Lowe J.A., Seeger T.F., Seymour P.A., Zorn S.H., Maloney P.R., Ewing F.E., Newman M.E., Schmidt A.W., Furman J.S., Robinson G.L., Jackson E., Johnson C., Morrone J.
Journal of Medicinal Chemistry , 1996
71.
Aminopyrimidines with High Affinity for Both Serotonin and Dopamine Receptors
Wustrow D., Belliotti T., Glase S., Kesten S.R., Johnson D., Colbry N., Rubin R., Blackburn A., Akunne H., Corbin A., Davis M.D., Georgic L., Whetzel S., Zoski K., Heffner T., et. al.
Journal of Medicinal Chemistry , 1998
72.
Electrophysiological and neurochemical evidence that pindolol has agonist properties at the 5-HT1A autoreceptor in vivo
Clifford E.M., Gartside S.E., Umbers V., Cowen P.J., Hajós M., Sharp T.
British Journal of Pharmacology , 1998
73.
Antagonist properties of (−)-pindolol and WAY 100635 at somatodendritic and postsynaptic 5-HT1A receptors in the rat brain
Corradetti R., Laaris N., Hanoun N., Laporte A., Le Poul E., Hamon M., Lanfumey L.
British Journal of Pharmacology , 1998
74.
Characterization of a 5-HT1B receptor on CHO cells: functional responses in the absence of radioligand binding
Giles H., Lansdell S.J., Bolofo M.-., Wilson H.L., Martin G.R.
British Journal of Pharmacology , 1996
75.
Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol
Hoey A., Jackson C., Pegg G., Sillence M.
British Journal of Pharmacology , 1996
76.
Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist
Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., Jones D.E., McLenachan A., Stanhope K.J., Critchley D.J., Childs K.J., Middlefell V.C., Lanfumey L., Corradetti R., Laporte A., et. al.
Behavioural Brain Research , 1995
77.
A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635.
Forster E.A., Cliffe I.A., Bill D.J., Dover G.M., Jones D., Reilly Y., Fletcher A.
European Journal of Pharmacology , 1995
78.
(S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors
Cliffe I.A., Brightwell C.I., Fletcher A., Forster E.A., Mansell H.L., Reilly Y., Routledge C., White A.C.
Journal of Medicinal Chemistry , 1993
79.
79
A. A. Krasnovskii
Dokl. Akad. Nauk SSSR , 1952
80.
Spiroxatrine: A selective serotonin1A receptor antagonist
Nelson D.L., Taylor E.W.
European Journal of Pharmacology , 1986
81.
N-[2-[(Substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines:  Synthesis and Wide Range of Antagonism at the Human 5-HT1A Receptor
Yasunaga T., Naito R., Kontani T., Tsukamoto S., Nomura T., Yamaguchi T., Mase T.
Journal of Medicinal Chemistry , 1997
82.
Synthesis and Pharmacological Characterization of Novel 6-Fluorochroman Derivatives as Potential 5-HT1A Receptor Antagonists
Yasunaga T., Kimura T., Naito R., Kontani T., Wanibuchi F., Yamashita H., Nomura T., Tsukamoto S., Yamaguchi T., Mase T.
Journal of Medicinal Chemistry , 1998
84.
Ketanserin and ritanserin discriminate between recombinant human 5-HT1Dα and 5-HT1Dβ receptor subtypes
Zgombick J.M., Schechter L.E., Kucharewicz S.A., Weinshank R.L., Branchek T.A.
European Journal of Pharmacology Molecular Pharmacology , 1995
85.
N-Methyl-5-tert-butyltryptamine:  A Novel, Highly Potent 5-HT1D Receptor Agonist
Xu Y., Schaus J.M., Walker C., Krushinski J., Adham N., Zgombick J.M., Liang S.X., Kohlman D.T., Audia J.E.
Journal of Medicinal Chemistry , 1999
86.
The Selective 5-HT1B Receptor Inverse Agonist 1‘-Methyl-5-[[2‘-methyl-4‘- (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4‘-piperidine] (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo
Gaster L.M., Blaney F.E., Davies S., Duckworth D.M., Ham P., Jenkins S., Jennings A.J., Joiner G.F., King F.D., Mulholland K.R., Wyman P.A., Hagan J.J., Hatcher J., Jones B.J., Middlemiss D.N., et. al.
Journal of Medicinal Chemistry , 1998
87.
5-HT1D receptor agonists and human coronary artery reactivity in vitro : crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519
LONGMORE J., BOULANGER C.M., DESTA B., HILL R.G., SCHOFIELD W.N., TAYLOR A.A.
British Journal of Clinical Pharmacology , 1996
88.
5-HT1B Receptor Antagonist Properties of Novel Arylpiperazide Derivatives of 1-Naphthylpiperazine
Jorand-Lebrun C., Pauwels P.J., Palmier C., Moret C., Chopin P., Perez M., Marien M., Halazy S.
Journal of Medicinal Chemistry , 1997
90.
Clinical and experimental effects of sumatriptan in humans.
Ferrari M.D., Saxena P.R.
Trends in Pharmacological Sciences , 1993
91.
Sumatriptan
Dechant K.L., Clissold S.P.
Drugs , 1992
92.
Sumatriptan
Perry C.M., Markham A.
Drugs , 1998
93.
Migraine: A Comprehensive Review of New Treatment Options
Weitzel K.W., Thomas M.L., Small R.E., Goode J.R.
Pharmacotherapy , 1999
94.
94
A. A. Krasnovskii
Fiziologiya Rastenii , 1957
96.
Regulation of Serotonin Release in the Frontal Cortex and Ventral Hippocampus of Homozygous Mice Lacking 5-HT1B Receptors: In Vivo Microdialysis Studies
Trillat A.-., Malagié I., Scearce K., Pons D., Anmella M.-., Jacquot C., Hen R., Gardier A.M.
Journal of Neurochemistry , 2002
97.
97
A. N. Terenin
Dokl. Akad. Nauk SSSR , 1952
99.
Synthesis and Serotonergic Activity of N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine and Analogs: Potent Agonists for 5-HT1D Receptors
Street L.J., Baker R., Davey W.B., Guiblin A.R., Jelley R.A., Reeve A.J., Routledge H., Sternfeld F., Watt A.P.
Journal of Medicinal Chemistry , 1995
101.
Zolmitriptan
Spencer C.M., Gunasekara N.S., Hills C.
Drugs , 1999
103.
103
L. N. Bell
Dokl. Akad. Nauk SSSR , 1956
104.
Effects of avitriptan, a new 5-HT1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential
Saxena P.R., Vries P.D., Wang W., Heiligers J.P., MaassenVanDenBrink A., Bax W.A., Yocca F.D.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1997
105.
Antimigraine drugs
Diener H.C., Kaube H., Limmroth V.
Journal of Neurology , 1999
106.
Effects of the Novel Antimigraine Agent, Frovatriptan, on Coronary and Cardiac Function in Dogs
Parsons A.A., Valocik R., Koster P., Raval P., Gagnon R., Tilford N., Feuerstein G.
Journal of Cardiovascular Pharmacology , 2003
107.
Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors
Perez M., Fourrier C., Sigogneau I., Pauwels P.J., Palmier C., John G.W., Valentin J., Halazy S.
Journal of Medicinal Chemistry , 1995
108.
L-694,247: a potent 5-HT1D receptor agonist
Beer M.S., Stanton J.A., Bevan Y., Heald A., Reeve A.J., Street L.J., Matassa V.G., Hargreaves R.J., Middlemiss D.N.
British Journal of Pharmacology , 1993
109.
[3H]L-694,247 labels the 5-HT1Dβ receptor in pig caudate membranes
Heald A., Stanton J.A., Osborne S., Middlemiss D.N., Beer M.S.
European Journal of Pharmacology , 1994
110.
Synthesis and serotonergic activity of 5-(oxadiazolyl)tryptamines: potent agonists for 5-HT1D receptors
Street L.J., Baker R., Castro J.L., Chambers M.S., Guiblin A.R., Hobbs S.C., Matassa V.G., Reeve A.J., Beer M.S.
Journal of Medicinal Chemistry , 1993
112.
Evolution of a Novel Series of [(N,N-Dimethylamino)propyl]- and Piperazinylbenzanilides as the First Selective 5-HT1D Antagonists
Clitherow J.W., Scopes D.I., Skingle M., Jordan C.C., Feniuk W., Campbell I.B., Carter M.C., Collington E.W., Connor H.E.
Journal of Medicinal Chemistry , 1994
113.
Benzylimidazolines as h5-HT1B/1D Serotonin Receptor Ligands: A Structure−Affinity Investigation
Law H., Dukat M., Teitler M., Lee D.K., Mazzocco L., Kamboj R., Rampersad V., Prisinzano T., Glennon R.A.
Journal of Medicinal Chemistry , 1998
114.
Synthesis and Evaluation of Pharmacological and Pharmacokinetic Properties of Monopropyl Analogs of 5-, 7-, and 8-[[(Trifluoromethyl)sulfonyl]oxy]-2-aminotetralins: Central Dopamine and Serotonin Receptor Activity
Sonesson C., Barf T., Nilsson J., Dijkstra D., Carlsson A., Svensson K., Smith M.W., Martin I.J., Duncan J.N.
Journal of Medicinal Chemistry , 1995
115.
5-HT1D Receptor Agonist Properties of Novel 2-[5-[[(Trifluoromethyl)sulfonyl]oxy]indolyl]ethylamines and Their Use as Synthetic Intermediates
Barf T.A., de Boer P., Wikström H., Peroutka S.J., Svensson K., Ennis M.D., Ghazal N.B., McGuire J.C., Smith M.W.
Journal of Medicinal Chemistry , 1996
116.
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(Piperidin-1-yl)propyl]indoles:  Agonists for the h5-HT1D Receptor with High Selectivity over the h5-HT1B Subtype
Castro J.L., Street L.J., Guiblin A.R., Jelley R.A., Russell M.G., Sternfeld F., Beer M.S., Stanton J.A., Matassa V.G.
Journal of Medicinal Chemistry , 1997
117.
Synthesis and Serotonergic Activity of 3-[2-(Pyrrolidin-1-yl)ethyl]indoles:  Potent Agonists for the h5-HT1D Receptor with High Selectivity over the h5-HT1B Receptor
Sternfeld F., Guiblin A.R., Jelley R.A., Matassa V.G., Reeve A.J., Hunt P.A., Beer M.S., Heald A., Stanton J.A., Sohal B., Watt A.P., Street L.J.
Journal of Medicinal Chemistry , 1999
118.
3-(Piperazinylpropyl)indoles:  Selective, Orally Bioavailable h5-HT1D Receptor Agonists as Potential Antimigraine Agents
Chambers M.S., Street L.J., Goodacre S., Hobbs S.C., Hunt P., Jelley R.A., Matassa V.G., Reeve A.J., Sternfeld F., Beer M.S., Stanton J.A., Rathbone D., Watt A.P., MacLeod A.M.
Journal of Medicinal Chemistry , 1999
119.
Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT1D Receptor Ligands with Improved Pharmacokinetic Profiles
van Niel M.B., Collins I., Beer M.S., Broughton H.B., Cheng S.K., Goodacre S.C., Heald A., Locker K.L., MacLeod A.M., Morrison D., Moyes C.R., O'Connor D., Pike A., Rowley M., Russell M.G., et. al.
Journal of Medicinal Chemistry , 1999
120.
Enhancement of Oral Absorption in Selective 5-HT1D Receptor Agonists:  Fluorinated 3-[3-(Piperidin-1-yl)propyl]indoles
Castro J.L., Collins I., Russell M.G., Watt A.P., Sohal B., Rathbone D., Beer M.S., Stanton J.A.
Journal of Medicinal Chemistry , 1998
123.
Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist
Neale R.F., Fallon S.L., Boyar W.C., Wasley J.W., Martin L.L., Stone G.A., Glaeser B.S., Sinton C.M., Williams M.
European Journal of Pharmacology , 1987
124.
124
V. V. Levchenko
Zhur. Obshch. Khim. , 1952
125.
Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents
Schlicker E., Werner U., Hamon M., Gozlan H., Nickel B., Szelenyi L., Göthert M.
British Journal of Pharmacology , 1992
126.
The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine
Petty M.A., Elands J., Johnson M.P., Linnik M.D., Hamel E., Moskowitz M.A., Lee W.S., McCarty D.R., Hibert M., Baron B.M.
European Journal of Pharmacology , 1997
128.
2-(1-Naphthyloxy)ethylamines with Enhanced Affinity for Human 5-HT1Dβ (h5-HT1B) Serotonin Receptors
Ismaiel A.M., Dukat M., Law H., Kamboj R., Fan E., Lee D.K., Mazzocco L., Buekschkens D., Teitler M., Pierson M.E., Glennon R.A.
Journal of Medicinal Chemistry , 1997
129.
129
J. Wiemann
Bull. Soc. chim. France , 1955
131.
GR127935 acts as a partial agonist at recombinant human 5-HT1Dα and 5-HT1Dβ receptors
Watson J.M., Burton M.J., Price G.W., Jones B.J., Middlemiss D.N.
European Journal of Pharmacology , 1996
132.
Computer-Aided Design and Synthesis of 5-Substituted Tryptamines and Their Pharmacology at the 5-HT1D Receptor: Discovery of Compounds with Potential Anti-Migraine Properties
Buckingham J., Glen R.C., Hill A.P., Hyde R.M., Martin G.R., Robertson A.D., Salmon J.A., Woollard P.M.
Journal of Medicinal Chemistry , 1995
133.
A Novel Series of 2,5-Substituted Tryptamine Derivatives as Vascular 5HT1B/1D Receptor Antagonists
Moloney G.P., Robertson A.D., Martin G.R., MacLennan S., Mathews N., Dodsworth S., Sang P.Y., Knight C., Glen R.
Journal of Medicinal Chemistry , 1997
134.
Synthesis and Serotonergic Activity of Substituted 2,N-Benzylcarboxamido-5-(2-ethyl-1-dioxoimidazolidinyl)-N,N-dimethyltrypt- amine Derivatives:  Novel Antagonists for the Vascular 5-HT1B-like Receptor
Moloney G.P., Martin G.R., Mathews N., Milne A., Hobbs H., Dodsworth S., Sang P.Y., Knight C., Williams M., Maxwell M., Glen R.C.
Journal of Medicinal Chemistry , 1999
135.
Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery
MacLean M.R., Clayton R.A., Templeton A.G., Morecroft I.
British Journal of Pharmacology , 1996
137.
Synthesis, Biological Activity, and Molecular Modeling Studies of Selective 5-HT2C/2B Receptor Antagonists
Forbes I.T., Dabbs S., Duckworth D.M., Ham P., Jones G.E., King F.D., Saunders D.V., Blaney F.E., Naylor C.B., Baxter G.S., Blackburn T.P., Kennett G.A., Wood M.D.
Journal of Medicinal Chemistry , 1996
138.
Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors
Schlicker E., Fink K., Molderings G.J., Price G.W., Duckworth M., Gaster L., Middlemiss D.N., Zentner J., Likungu J., Göthert M.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1997
141.
Possible Antimigraine Mechanisms of Action of the 5HT1F Receptor Agonist LY334370
Shepheard S., Edvinsson L., Cumberbatch M., Williamson D., Mason G., Webb J., Boyce S., Hill R., Hargreaves R.
Cephalalgia , 1999
143.
5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs
Johnson K.W., Schaus J.M., Durkin M.M., Audia J.E., Kaldor S.W., Flaugh M.E., Adham N., Zgombick J.M., Cohen M.L., Branchek T.A., Phebus L.A.
NeuroReport , 2004
145.
145
Friedl.
146.
Activation of 5-HT 2B Receptors in the Medial Amygdala causes Anxiolysis in the Social Interaction Test in the Rat
DUXON M.S., KENNETT G.A., LIGHTOWLER S., BLACKBURN T.P., FONE K.C.
Neuropharmacology , 1997
147.
BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats
Kennett G.A., Ainsworth K., Trail B., Blackburn T.P.
Neuropharmacology , 1997
149.
Influence of amine substituents on 5-HT2A versus 5-HT2C binding of phenylalkyl- and indolylalkylamines.
Glennon R.A., Dukat M., El-Bermawy M., Law H., De Los Angeles J., Teitler M., King A., Herrick-Davis K.
Journal of Medicinal Chemistry , 1994
150.
Thieno[3,2-b]- and Thieno[2,3-b]pyrrole Bioisosteric Analogues of the Hallucinogen and Serotonin Agonist N,N-Dimethyltryptamine
Blair J.B., Marona-Lewicka D., Kanthasamy A., Lucaites V.L., Nelson D.L., Nichols D.E.
Journal of Medicinal Chemistry , 1999
151.
Further Studies on Oxygenated Tryptamines with LSD-like Activity Incorporating a Chiral Pyrrolidine Moiety into the Side Chain
Gerasimov M., Marona-Lewicka D., Kurrasch-Orbaugh D.M., Qandil A.M., Nichols D.E.
Journal of Medicinal Chemistry , 1999
153.
Stereoselective Synthesis of trans-2-(Indol-3-yl)cyclopropylamines: Rigid Tryptamine Analogs
Vangveravong S., Nichols D.E.
Journal of Organic Chemistry , 1995
154.
Synthesis and Serotonin Receptor Affinities of a Series of trans-2-(Indol-3-yl)cyclopropylamine Derivatives
Vangveravong S., Kanthasamy A., Lucaites V.L., Nelson D.L., Nichols D.E.
Journal of Medicinal Chemistry , 1998
156.
m-CPP: a tool for studying behavioural responses associated with 5-HT1c receptors
Curzon G., Kennett G.A.
Trends in Pharmacological Sciences , 1990
157.
Effect of chronic m -CPP on locomotion, hypophagia, plasma corticosterone and 5-HT2C receptor levels in the rat
Fone K.C., Austin R.H., Topham I.A., Kennett G.A., Punhani T.
British Journal of Pharmacology , 1998
158.
158
Friedl.
159.
Effects of the receptor agonist 1-(3-chlorophenyl)piperazine on plasma glucose levels of rats
Sugimoto Y., Yamada J., Yoshikawa T., Horisaka K.
European Journal of Pharmacology , 1996
160.
160
1912
162.
Synthesis and evaluation of a novel series of N,N-dimethylisotryptamines
Glennon R.A., Jacyno J.M., Young R., McKenney J.D., Nelson D.
Journal of Medicinal Chemistry , 1984
163.
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity
Glennon R.A., Raghupathi R., Bartyzel P., Teitler M., Leonhardt S.
Journal of Medicinal Chemistry , 1992
164.
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: A Potent Serotonin 5-HT2A/2C Agonist
Nichols D.E., Frescas S., Marona-Lewicka D., Huang X., Roth B.L., Gudelsky G.A., Nash J.F.
Journal of Medicinal Chemistry , 1994
165.
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors.
Seggel M.R., Yousif M.Y., Lyon R.A., Titeler M., Roth B.L., Suba E.A., Glennon R.A.
Journal of Medicinal Chemistry , 1990
166.
Dihydrobenzofuran Analogues of Hallucinogens. 3. Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigidified Methoxy Groups
Monte A.P., Marona-Lewicka D., Parker M.A., Wainscott D.B., Nelson D.L., Nichols D.E.
Journal of Medicinal Chemistry , 1996
167.
Dihydrobenzofuran Analogues of Hallucinogens. 4. Mescaline Derivatives
Monte A.P., Waldman S.R., Marona-Lewicka D., Wainscott D.B., Nelson D.L., Sanders-Bush E., Nichols D.E.
Journal of Medicinal Chemistry , 1997
168.
Substituted Naphthofurans as Hallucinogenic Phenethylamine−Ergoline Hybrid Molecules with Unexpected Muscarinic Antagonist Activity
Monte A.P., Marona-Lewicka D., Lewis M.M., Mailman R.B., Wainscott D.B., Nelson D.L., Nichols D.E.
Journal of Medicinal Chemistry , 1998
169.
A Novel (Benzodifuranyl)aminoalkane with Extremely Potent Activity at the 5-HT2A Receptor
Parker M.A., Marona-Lewicka D., Lucaites V.L., Nelson D.L., Nichols D.E.
Journal of Medicinal Chemistry , 1998
170.
2,3-Dihydrobenzofuran analogs of hallucinogenic phenethylamines
Nichols D.E., Snyder S.E., Oberlender R., Johnson M.P., Huang X.
Journal of Medicinal Chemistry , 1991
171.
[125I]-2-(2,5-Dimethoxy-4-Iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex
Johnson M.P., Mathis C.A., Shulgin A.T., Hoffman A.J., Nichols D.E.
Pharmacology Biochemistry and Behavior , 1990
173.
Potent, Selective Tetrahydro-β-carboline Antagonists of the Serotonin 2B (5HT2B) Contractile Receptor in the Rat Stomach Fundus
Audia J.E., Evrard D.A., Murdoch G.R., Droste J.J., Nissen J.S., Schenck K.W., Fludzinski P., Lucaites V.L., Nelson D.L., Cohen M.L.
Journal of Medicinal Chemistry , 1996
174.
174
S. Calvert
India Rubber Tire Rev. , 1926
175.
175
I. Mayer
1966
176.
176
G. V. Samsonov
"Metody Ispytaniya na Mikrotverdost' i Pribory" (Methods of Microhardness Testing and Apparatus) , 1965
177.
177
J. Henry
Proc. R. Irish Acad. , 1945
179.
179
Chem. Abs. , 1947
180.
180
1946
181.
(8.beta.)-6-Methylergoline amide derivatives as serotonin antagonists: N1-substituent effects on vascular 5HT2 receptor activity
Misner J.W., Garbrecht W.L., Marzoni G., Whitten K.R., Cohen M.L.
Journal of Medicinal Chemistry , 1990
183.
N(1)-substituted ergolines and tryptamines show species differences for the agonist-labeled 5-HT2 receptor.
Johnson M.P., Audia J.E., Nissen J.S., Nelson D.L.
European Journal of Pharmacology , 1993
184.
184
F. Haurowitz
"The Chemistry and Function of Proteins" , 1965
185.
185
1954
187.
(8.beta.)-Ergoline-8-carboxylic acid cycloalkyl esters as serotonin antagonists: structure-activity study
Garbrecht W.L., Marzoni G., Whitten K.R., Cohen M.L.
Journal of Medicinal Chemistry , 1988
188.
Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat
Kalkman H.O., Neumann V., Nozulak J., Tricklebank M.D.
European Journal of Pharmacology , 1998
189.
Role of 5-HT2A and 5-HT2C Receptor Subtypes in the Two Types of Fear Generated by the Elevated T-Maze
Mora P.O., Netto C.F., Graeff F.G.
Pharmacology Biochemistry and Behavior , 1997
190.
(+)-cis-4,5,7a,8,9,10,11,11a-Octahydro-7H-10-methylindolo[1,7-bc][2,6]- naphthyridine: A 5-HT2C/2B Receptor Antagonist with Low 5-HT2A Receptor Affinity
Nozulak J., Kalkman H.O., Floerscheim P., Hoyer D., Schoeffter P., Buerki H.R.
Journal of Medicinal Chemistry , 1995
191.
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
Leysen J.E., Awouters F., Kennis L., Laduron P.M., Vandenberk J., Janssen P.A.
Life Sciences , 1981
192.
Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors
Pierce P.A., Kim J.Y., Peroutka S.J.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1992
194.
194
A. A. Vertman
"Svoistva Rasplavov Zheleza" (Properties of Iron Melts) , 1969
195.
Syntheses of 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives
Watanabe Y., Usui H., Kobayashi S., Yoshiwara H., Shibano T., Tanaka T., Morishima Y., Yasuoka M., Kanao M.
Journal of Medicinal Chemistry , 1992
196.
196
E. Müller
Z. Elektrochem. , 1910
197.
Ketanserin analogs: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding
Herndon J.L., Ismaiel A., Ingher S.P., Teitler M., Glennon R.A.
Journal of Medicinal Chemistry , 1992
198.
198
W. Cohen
Rec. Trav. chim. , 1919
199.
Dopamine receptor pharmacology.
Seeman P., Van Tol H.H.
Trends in Pharmacological Sciences , 1994
200.
Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT1C-selective antagonist
Ismaiel A.M., De Los Angeles J., Teitler M., Ingher S., Glennon R.A.
Journal of Medicinal Chemistry , 1993
201.
Spiperone:  Influence of Spiro Ring Substituents on 5-HT2A Serotonin Receptor Binding
Metwally K.A., Dukat M., Egan C.T., Smith C., DuPre A., Gauthier C.B., Herrick-Davis K., Teitler M., Glennon R.A.
Journal of Medicinal Chemistry , 1998
202.
Effect of N-alkylation on the affinities of analogs of spiperone for dopamine D2 and serotonin 5-HT2 receptors
Mach R.H., Jackson J.R., Luedtke R.R., Ivins K.J., Molinoff P.B., Ehrenkaufer R.L.
Journal of Medicinal Chemistry , 1992
203.
RS-102221: A Novel High Affinity and Selective, 5-HT 2C Receptor Antagonist
BONHAUS D.W., WEINHARDT K.K., TAYLOR M., DESOUZA A., MCNEELEY P.M., SZCZEPANSKI K., FONTANA D.J., TRINH J., ROCHA C.L., DAWSON M.W., FLIPPIN L.A., EGLEN R.M.
Neuropharmacology , 1997
204.
Absorption and Brain Penetration of a High Affinity, Highly Selective 5-HT2C Receptor Antagonist, RS-102221
BONHAUS D.W., ROCHA C.L., DAWSON M.W., EGLEN R.M.
Annals of the New York Academy of Sciences , 1998
205.
N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea hydrochloride: the first selective 5-HT1C receptor antagonist
Forbes I.T., Kennett G.A., Gadre A., Ham P., Hayward C.J., Martin R.T., Thompson M., Wood M.D., Baxter G.S.
Journal of Medicinal Chemistry , 1993
206.
5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: A Novel 5-HT2C/5-HT2B Receptor Antagonist with Improved Affinity, Selectivity, and Oral Activity
Forbes I.T., Ham P., Booth D.H., Martin R.T., Thompson M., Baxter G.S., Blackburn T.P., Glen A., Kennett G.A., Wood M.D.
Journal of Medicinal Chemistry , 1995
207.
N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT2B Receptor Antagonist
Forbes I.T., Jones G.E., Murphy O.E., Holland V., Baxter G.S.
Journal of Medicinal Chemistry , 1995
208.
1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT2A Partial Agonists
Dowd C.S., Herrick-Davis K., Egan C., DuPre A., Smith C., Teitler M., Glennon R.A.
Journal of Medicinal Chemistry , 2000
209.
Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia
Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S.
Schizophrenia Research , 1991
212.
Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists
Kuoppamäki M., Syvälahti E., Hietala J.
European Journal of Pharmacology Molecular Pharmacology , 1993
213.
New Antipsychotic Agents with Serotonin and Dopamine Antagonist Properties Based on a Pyrrolo[2,1-b][1,3]benzothiazepine Structure
Campiani G., Nacci V., Bechelli S., Ciani S.M., Garofalo A., Fiorini I., Wikström H., de Boer P., Liao Y., Tepper P.G., Cagnotto A., Mennini T.
Journal of Medicinal Chemistry , 1998
214.
214
L. V. Pavlova
1965
216.
216
A. P. Tomilov
Zhur. Prikl. Khim. , 1959
218.
Development of a Receptor-Interaction Model for Serotonin 5-HT2 Receptor Antagonists. Predicting Selectivity with Respect to Dopamine D2 Receptors
Andersen K., Liljefors T., Gundertofte K., Perregaard J., Bogeso K.P.
Journal of Medicinal Chemistry , 1994
220.
5-HT1 and 5-HT2 binding profiles of the serotonergic agents .alpha.-methylserotonin and 2-methylserotonin
Ismaiel A.M., Titeler M., Miller K.J., Smith T.S., Glennon R.A.
Journal of Medicinal Chemistry , 1990
221.
5-Methoxytryptamine and 2-methyl-5-hydroxytryptamine-induced desensitization as a discriminative tool for the 5-HT3 and putative 5-HT4 receptors in guinea pig ileum
Craig D.A., Eglen R.M., Walsh L.K., Perkins L.A., Whiting R.L., Clarke D.E.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1990
222.
[3H]quipazine labels 5-HT3 recognition sites in rat cortical membranes.
Peroutka S.J., Hamik A.
European Journal of Pharmacology , 1988
223.
Characteristics of 5‐HT3 binding sites in NG108‐15, NCB‐20 neuroblastoma cells and rat cerebral cortex using [3H]‐quipazine and [3H]‐GR65630 binding
Sharif N.A., Wong E.H., Loury D.N., Stefanich E., Michel A.D., Eglen R.M., Whiting R.L.
British Journal of Pharmacology , 1991
225.
Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.
Glennon R.A., Ismaiel A.E., McCarthy B.M., Peroutka S.J.
European Journal of Pharmacology , 1989
226.
SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo
Bachy A., Héaulme M., Giudice A., Michaud J., Lefevre I.A., Souilhac J., Manara L., Emerit M.B., Gozlan H., Hamon M., Keane P.E., Soubrié P., Le Fur G.
European Journal of Pharmacology , 1993
227.
5-HT3-like receptors in the rat medial prefrontal cortex: further pharmacological characterization
Edwards E., Hampton E., Ashby C.R., Zhang J., Wang R.Y.
Brain Research , 1996
228.
Novel, Potent, and Selective 5-HT3 Receptor Antagonists Based on the Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and Comparative Molecular Field Analysis Studies
Anzini M., Cappelli A., Vomero S., Giorgi G., Langer T., Hamon M., Merahi N., Emerit B.M., Cagnotto A., Skorupska M., Mennini T., Pinto J.C.
Journal of Medicinal Chemistry , 1995
229.
1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT3 receptor agonist.
Kilpatrick G.J., Butler A., Burridge J., Oxford A.W.
European Journal of Pharmacology , 1990
233.
Structure−Activity Relationships for the Binding of Arylpiperazines and Arylbiguanides at 5-HT3 Serotonin Receptors
Dukat M., Abdel-Rahman A.A., Ismaiel A.M., Ingher S., Teitler M., Gyermek L., Glennon R.A.
Journal of Medicinal Chemistry , 1996
234.
Novel and Highly Potent 5-HT3 Receptor Agonists Based on a Pyrroloquinoxaline Structure
Campiani G., Cappelli A., Nacci V., Anzini M., Vomero S., Hamon M., Cagnotto A., Fracasso C., Uboldi C., Caccia S., Consolo S., Mennini T.
Journal of Medicinal Chemistry , 1997
235.
Novel and Selective Partial Agonists of 5-HT3 Receptors. 2. Synthesis and Biological Evaluation of Piperazinopyridopyrrolopyrazines, Piperazinopyrroloquinoxalines, and Piperazinopyridopyrroloquinoxalines
Prunier H., Rault S., Lancelot J., Robba M., Renard P., Delagrange P., Pfeiffer B., Caignard D., Misslin R., Béatrice Guardiola-Lemaitre, and, Hamon M.
Journal of Medicinal Chemistry , 1997
236.
Novel Selective and Partial Agonists of 5-HT3 Receptors. Part 1. Synthesis and Biological Evaluation of Piperazinopyrrolothienopyrazines
Rault S., Lancelot J., Prunier H., Robba M., Renard P., Delagrange P., Pfeiffer B., Caignard D., Guardiola-Lemaitre B., Hamon M.
Journal of Medicinal Chemistry , 1996
237.
Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT3 Receptor Agonists:  Synthesis, Further Structure−Activity Relationships, and Biological Studies
Campiani G., Morelli E., Gemma S., Nacci V., Butini S., Hamon M., Novellino E., Greco G., Cagnotto A., Goegan M., Cervo L., Dalla Valle F., Fracasso C., Caccia S., Mennini T., et. al.
Journal of Medicinal Chemistry , 1999
238.
Novel Potent and Selective Central 5-HT3 Receptor Ligands Provided with Different Intrinsic Efficacy. 1. Mapping the Central 5-HT3 Receptor Binding Site by Arylpiperazine Derivatives
Cappelli A., Anzini M., Vomero S., Mennuni L., Makovec F., Doucet E., Hamon M., Bruni G., Romeo M.R., Menziani M.C., De Benedetti P.G., Langer T.
Journal of Medicinal Chemistry , 1998
239.
Molecular structure and dynamics of some potent 5-HT3 receptor antagonists. Insight into the interaction with the receptor.
Cappelli A., Donati A., Anzini M., Vomero S., De Benedetti P.G., Menziani M.C., Langer T.
Bioorganic and Medicinal Chemistry , 1996
240.
Novel Potent and Selective Central 5-HT3 Receptor Ligands Provided with Different Intrinsic Efficacy. 2. Molecular Basis of the Intrinsic Efficacy of Arylpiperazine Derivatives at the Central 5-HT3 Receptors
Cappelli A., Anzini M., Vomero S., Canullo L., Mennuni L., Makovec F., Doucet E., Hamon M., Menziani M.C., De Benedetti P.G., Bruni G., Romeo M.R., Giorgi G., Donati A.
Journal of Medicinal Chemistry , 1999
241.
Novel antagonists of 5-HT3 receptors. Synthesis and biological evaluation of piperazinylquinoxaline derivatives
Monge A., Palop J.A., Del Castillo J.C., Caldero J.M., Roca J., Romero G., Del Rio J., Lasheras B.
Journal of Medicinal Chemistry , 1993
242.
Blockade of neuronal tryptamine receptors by metoclopramide
Fozard J.R., Mobarok Ali A.T.
European Journal of Pharmacology , 1978
243.
5-HT3 receptors are membrane ion channels
Derkach V., Surprenant A., North R.A.
Nature , 1989
244.
The Antiemetic Profile of Zacopride
Smith W.L., Alphin R.S., Jackson C.B., Sancilio L.F.
Journal of Pharmacy and Pharmacology , 1989
245.
Zacopride, a potent 5-HT3 antagonist
Smith W.W., Sancilio L.F., Owera-Atepo J.B., Naylor R.J., Lambert L.
Journal of Pharmacy and Pharmacology , 1988
246.
MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors
Fozard J.R.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1984
247.
5-Hydroxytryptamine (5-HT3) receptor antagonists. 3. Ortho-substituted phenylureas
Bermudez J., Dabbs S., King F.D.
Journal of Medicinal Chemistry , 1990
248.
5-Hydroxytryptamine (5-HT3) receptor antagonists. 2. 1-Indolinecarboxamides
Bermudez J., Dabbs S., Joiner K.A., King F.D.
Journal of Medicinal Chemistry , 1990
249.
Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists
Turconi M., Nicola M., Gil Quintero M., Maiocchi L., Micheletti R., Giraldo E., Donetti A.
Journal of Medicinal Chemistry , 1990
250.
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives
Bermudez J., Fake C.S., Joiner G.F., Joiner K.A., King F.D., Miner W.D., Sanger G.J.
Journal of Medicinal Chemistry , 1990
251.
N-(Quinuclidin-3-yl)-2-(1-methyl-1H-indol-3-yl)-2-oxo-acetamide: a high affinity 5-HT3 receptor partial agonist
Clark R.D., Muchowski J.M., Weinhardt K.K., Dillon M.P., Lee C., Bley K.R., Bonhaus D.W., Wong E.H., Eglen R.M.
Bioorganic and Medicinal Chemistry Letters , 1995
252.
5‐HT3 receptors
Kilpatrick G.J., Bunce K.T., Tyers M.B.
Medicinal Research Reviews , 1990
253.
Pharmacological properties of GR38032F, a novel antagonist at 5‐HT3 receptors
Butler A., Hill J.M., Ireland S.J., Jordan C.C., Tyers M.B.
British Journal of Pharmacology , 1988
255.
255
Tomita M
Chem. Abs. , 1939
256.
Phenylimidazolidin-2-one Derivatives as Selective 5-HT3 Receptor Antagonists and Refinement of the Pharmacophore Model for 5-HT3 Receptor Binding
Heidempergher F., Pillan A., Pinciroli V., Vaghi F., Arrigoni C., Bolis G., Caccia C., Dho L., McArthur R., Varasi M.
Journal of Medicinal Chemistry , 1997
257.
Novel 5-HT3 antagonists. Indole oxadiazoles
Swain C.J., Baker R., Kneen C., Moseley J., Saunders J., Seward E.M., Stevenson G., Beer M., Stanton J., Watling K.
Journal of Medicinal Chemistry , 1991
258.
The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist.
Takemi F., Michihide S., Ken-ichi I., Hidenori S., Tetsuya T.
European Journal of Pharmacology , 1991
259.
The Effects of Orally Administered Y-25130, a Selective Serotonin3-Receptor Antagonist, on Chemotherapeutic Agent-Induced Emesis
Haga K., Inaba K., Shoji H., Morimoto Y., Fukuda T., Setoguchi M.
The Japanese Journal of Pharmacology , 1993
260.
Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships
Robertson D.W., Lacefield W.B., Bloomquist W., Pfeifer W., Simon R.L., Cohen M.L.
Journal of Medicinal Chemistry , 1992
261.
Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists
Rosen T., Nagel A.A., Rizzi J.P., Ives J.L., Daffeh J.B., Ganong A.H., Guarino K., Heym J., McLean S.
Journal of Medicinal Chemistry , 1990
262.
262
C. Friedel
Ann. Chim. Phys. , 1876
263.
Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)oxazoles)
Swain C.J., Baker R., Kneen C., Herbert R., Moseley J., Saunders J., Seward E.M., Stevenson G.I., Beer M.
Journal of Medicinal Chemistry , 1992
264.
2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
Clark R.D., Miller A.B., Berger J., Repke D.B., Weinhardt K.K., Kowalczyk B.A., Eglen R.M., Bonhaus D.W., Lee C.H.
Journal of Medicinal Chemistry , 1993
265.
5-HT3 Antagonists Derived from Aminopyridazine-type Muscarinic M1 Agonists
Rival Y., Hoffmann R., Didier B., Rybaltchenko V., Bourguignon J., Wermuth C.G.
Journal of Medicinal Chemistry , 1998
266.
Benzoxazole Derivatives as Novel 5-HT3 Receptor Partial Agonists in the Gut
Sato Y., Yamada M., Yoshida S., Soneda T., Ishikawa M., Nizato T., Suzuki K., Konno F.
Journal of Medicinal Chemistry , 1998
267.
A New 5-HT3 Receptor Ligand. II. Structure-Activity Analysis of 5-HT3 Receptor Agonist Action in the Gut.
YAMADA M., SATO Y., KOBAYASHI K., KONNO F., SONEDA T., WATANABE T.
Chemical and Pharmaceutical Bulletin , 2011
268.
The 5‐HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.
Gerald C., Adham N., Kao H.T., Olsen M.A., Laz T.M., Schechter L.E., Bard J.A., Vaysse P.J., Hartig P.R., Branchek T.A.
EMBO Journal , 1995
270.
SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum
Buchheit K., Gamse R., Pfannkuche H.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1992
271.
SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype
Flynn D.L., Zabrowski D.L., Becker D.P., Nosal R., Villamil C.I., Gullikson G.W., Moummi C., Yang D.C.
Journal of Medicinal Chemistry , 1992
272.
BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties
Blackburn T.P., Baxter G.S., Kennett G.A., King F.D., Piper D.C., Sanger G.J., Thomas D.R., Upton N., Wood M.D.
Psychopharmacology , 1993
273.
Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants
King F.D., Hadley M.S., Joiner K.T., Martin R.T., Sanger G.J., Smith D.M., Smith G.E., Smith P., Turner D.H., Watts E.A.
Journal of Medicinal Chemistry , 1993
274.
Synthesis and pharmacological activity of a macrocyclic benzamide
Langlois M., Yang D., Brémont B., Shen S.
Bioorganic and Medicinal Chemistry Letters , 1995
275.
Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo
Eglen R.M., Bonhaus D.W., Johnson L.G., Leung E., Clark R.D.
British Journal of Pharmacology , 1995
277.
New Esters of 4-Amino-5-chloro-2-methoxybenzoic Acid as Potent Agonists and Antagonists for 5-HT4 Receptors
Yang D., Soulier J., Sicsic S., Mathé-Allainmat M., Brémont B., Croci T., Cardamone R., Aureggi G., Langlois M.
Journal of Medicinal Chemistry , 1997
278.
RS 39604: a potent, selective and orally active 5‐HT4 receptor antagonist
Hegde S.S., Bonhaus D.W., Johnson L.G., Leung E., Clark R.D., Eglen R.M.
British Journal of Pharmacology , 1995
279.
Central 5-HT4 receptors.
Eglen R.
Trends in Pharmacological Sciences , 1995
280.
RS 23597‐190: a potent and selective 5‐HT4 receptor antagonist
Eglen R.M., Bley K., Bonhaus D.W., Clark R.D., Hegde S.S., Johnson L.G., Leung E., Wong E.H.
British Journal of Pharmacology , 1993
281.
Rs-100235: A high affinity 5-HT4 receptor antagonist
Clark R.D., Jahangir A., Flippin L.A., Langston J.A., Leung E., Bonhaus D.W., Wong E.H., Johnson L.G., Eglen R.M.
Bioorganic and Medicinal Chemistry Letters , 1995
282.
Blockade of human atrial 5-HT4 receptors by SB 207710, a selective and high affinity 5-HT4 receptor antagonist
Kaumann A.J., Gaster L.M., King F.D., Brown A.M.
Naunyn-Schmiedeberg's Archives of Pharmacology , 1994
283.
(1-Butyl-4-piperidinyl)methyl 8-amino-7-chloro-1,4-benzodioxane-5-carboxylate hydrochloride: a highly potent and selective 5-HT4 receptor antagonist derived from metoclopramide
Gaster L.M., Jennings A.J., Joiner G.F., King F.D., Mulholland K.R., Rahman S.K., Starr S., Wyman P.A., Wardle K.A.
Journal of Medicinal Chemistry , 1993
284.
GR113808: a novel, selective antagonist with high affinity at the 5‐HT4 receptor
Gale J.D., Grossman C.J., Whitehead J.W., Oxford A.W., Bunce K.T., Humphrey P.P.
British Journal of Pharmacology , 1994
285.
N-[(1-Butyl-4-piperidinyl)methyl]-3,4- dihydro-2H-[1,3]oxazino[3,2-a]indole- 10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity.
Gaster L.M., Joiner G.F., King F.D., Wyman P.A., Sutton J.M., Bingham S., Ellis E.S., Sanger G.J., Wardle K.A.
Journal of Medicinal Chemistry , 1995
287.
The Serotonin 5-HT4 Receptor. 1. Design of a New Class of Agonists and Receptor Map of the Agonist Recognition Site
Buchheit K., Gamse R., Giger R., Hoyer D., Klein F., Kloeppner E., Pfannkuche H., Mattes H.
Journal of Medicinal Chemistry , 1995
288.
The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists
Buchheit K., Gamse R., Giger R., Hoyer D., Klein F., Kloeppner E., Pfannkuche H., Mattes H.
Journal of Medicinal Chemistry , 1995
289.
Synthesis of 2-Piperazinylbenzothiazole and 2-Piperazinylbenzoxazole Derivatives with 5-HT3 Antagonist and 5-HT4 Agonist Properties
Monge A., Pena M.D., Palop J.A., Caldero J.M., Roca J., Garcia E., Romero G., del Rio J., Lasheras B.
Journal of Medicinal Chemistry , 1994
290.
Synthesis and Structure−Activity Relationships of Potent and Orally Active 5-HT4 Receptor Antagonists:  Indazole and Benzimidazolone Derivatives
Schaus J.M., Thompson D.C., Bloomquist W.E., Susemichel A.D., Calligaro D.O., Cohen M.L.
Journal of Medicinal Chemistry , 1998
291.
Arylcarbamate Derivatives of 1-Piperidineethanol as Potent Ligands for 5-HT4 Receptors
Soulier J., Yang D., Brémont B., Croci T., Guzzi U., Langlois M.
Journal of Medicinal Chemistry , 1997
292.
292
Pechernikova Z P
Zavod. Lab. , 1978
294.
294
H. I. Schlesinger
J. Am. Chem. Soc. , 1937
295.
(R)-3,N-Dimethyl-N-[1-methyl-3-(4-methylpiperidin-1-yl)propyl]benzenesulfonamide:  The First Selective 5-HT7 Receptor Antagonist
Forbes I.T., Dabbs S., Duckworth D.M., Jennings A.J., King F.D., Lovell P.J., Brown A.M., Collin L., Hagan J.J., Middlemiss D.N., Riley G.J., Thomas D.R., Upton N.
Journal of Medicinal Chemistry , 1998
296.
2-Substituted Tryptamines:  Agents with Selectivity for 5-HT6 Serotonin Receptors
Glennon R.A., Lee M., Rangisetty J.B., Dukat M., Roth B.L., Savage J.E., McBride A., Rauser L., Hufeisen S., Lee D.K.
Journal of Medicinal Chemistry , 2000